Adequate vitamin D status is essential for skeletal health. Paget's disease of bone (PDB) is a common metabolic skeletal disorder, but data regarding the vitamin D status in PDB patients are lacking. We performed a case-control study to estimate vitamin D status in 708 PDB patients and in 1803 healthy controls from Italy and an observational prospective study to evaluate the efficacy-safety profile of oral cholecalciferol treatment [400.000 International Units (UI) of cholecalciferol administered in cycles of 8 weeks until 25OHD levels reaches 70 nmol/L as primary therapy and 50.000 UI of cholecalciferol administered every 2 weeks for 52 weeks for the maintenance therapy] in 82 PDB patients with hypovitaminosis D, i.e., 25OHD < 50 nmol/L. The main outcome measures for the prospective study were 25OHD levels, metabolic risk factors (RF) for nephrolithiasis, bone pain score (BPS), and pain medication score (PMS). Over half of PDB patients had hypovitaminosis D. Among PDB patients treated with cholecalciferol, 76 patients reached 25OHD levels ≥ 70 nmol/L after the first cycle of primary therapy and the remaining six patients after a second cycle. The maintenance therapy guaranteed 25OHD levels ≥ 70 nmol/L during the entire follow-up. The increase in 25OHD levels reduced PTH, BPS, and PMS levels, without changes in RF for nephrolithiasis. We can conclude that (i) hypovitaminosis D is frequent in PDB patients, (ii) cholecalciferol significantly increased 25OHD levels in PDB patients, and (iii) the correction of hypovitaminosis D improves the quality of life of PDB patients without inducing significant changes in RF for nephrolithiasis.

Vitamin D Status in Paget Disease of Bone and Efficacy–Safety Profile of Cholecalciferol Treatment in Pagetic Patients with Hypovitaminosis D / Rendina, D.; De Filippo, G.; Merlotti, D.; Di Stefano, M.; Succoio, M.; Muggianu, S. M.; Bianciardi, S.; D'Elia, L.; Coppo, C.; Faraonio, R.; Nuti, R.; Strazzullo, P.; Gennari, L.. - In: CALCIFIED TISSUE INTERNATIONAL. - ISSN 0171-967X. - 105:4(2019), pp. 412-422. [10.1007/s00223-019-00578-1]

Vitamin D Status in Paget Disease of Bone and Efficacy–Safety Profile of Cholecalciferol Treatment in Pagetic Patients with Hypovitaminosis D

Rendina D.;Di Stefano M.;Succoio M.;Coppo C.;Faraonio R.;Strazzullo P.;Gennari L.
2019

Abstract

Adequate vitamin D status is essential for skeletal health. Paget's disease of bone (PDB) is a common metabolic skeletal disorder, but data regarding the vitamin D status in PDB patients are lacking. We performed a case-control study to estimate vitamin D status in 708 PDB patients and in 1803 healthy controls from Italy and an observational prospective study to evaluate the efficacy-safety profile of oral cholecalciferol treatment [400.000 International Units (UI) of cholecalciferol administered in cycles of 8 weeks until 25OHD levels reaches 70 nmol/L as primary therapy and 50.000 UI of cholecalciferol administered every 2 weeks for 52 weeks for the maintenance therapy] in 82 PDB patients with hypovitaminosis D, i.e., 25OHD < 50 nmol/L. The main outcome measures for the prospective study were 25OHD levels, metabolic risk factors (RF) for nephrolithiasis, bone pain score (BPS), and pain medication score (PMS). Over half of PDB patients had hypovitaminosis D. Among PDB patients treated with cholecalciferol, 76 patients reached 25OHD levels ≥ 70 nmol/L after the first cycle of primary therapy and the remaining six patients after a second cycle. The maintenance therapy guaranteed 25OHD levels ≥ 70 nmol/L during the entire follow-up. The increase in 25OHD levels reduced PTH, BPS, and PMS levels, without changes in RF for nephrolithiasis. We can conclude that (i) hypovitaminosis D is frequent in PDB patients, (ii) cholecalciferol significantly increased 25OHD levels in PDB patients, and (iii) the correction of hypovitaminosis D improves the quality of life of PDB patients without inducing significant changes in RF for nephrolithiasis.
2019
Vitamin D Status in Paget Disease of Bone and Efficacy–Safety Profile of Cholecalciferol Treatment in Pagetic Patients with Hypovitaminosis D / Rendina, D.; De Filippo, G.; Merlotti, D.; Di Stefano, M.; Succoio, M.; Muggianu, S. M.; Bianciardi, S.; D'Elia, L.; Coppo, C.; Faraonio, R.; Nuti, R.; Strazzullo, P.; Gennari, L.. - In: CALCIFIED TISSUE INTERNATIONAL. - ISSN 0171-967X. - 105:4(2019), pp. 412-422. [10.1007/s00223-019-00578-1]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/772847
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 9
social impact